Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...

Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...

In 2022, Alnylam filed a patent infringement lawsuit against Moderna, claiming it violated a newly obtained patent. The claim ...

--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

CAMBRIDGE, MA—Kevin Joseph Fitzgerald, the Chief Scientific Officer and Executive Vice President, Head of Research at Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), recently sold a significant portion ...